6413 results for "11+1双色球多少钱一注"

in 22.41 milliseconds.

• BLUEPRINT release August 2015, Bisulfite-Seq for effector memory CD8-positive, alpha-beta T cell, on genome GRCh38

  Bisulfite-Seq data for 1 effector memory CD8-positive, alpha-beta T cell sample(s). 11 run(s), 1 experiment(s), 1 alignment(s) on human genome GRCh38. Part of BLUEPRINT release August 2015. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20150820/homo_sapiens/README_bisulphite_analysis_CNAG_20150820

  Dataset EGAD00001001583

• Single-cell long-read transcriptomes from CH, MDS and AML patients with CH mutations

  Single-cell long-read (ONT) transcriptome sequencing from CH (n = 3), MDS (n = 5, MDS02 in 2 replicates) and AML (n =1, in 2 replicates) samples with mutations in splicing factors (SF3B1 - n = 8, U2AF1 n = 1) or transcription regulators (DNMT3A - CH04). Full length cDNA from 10x Genomics 3' V3.

  Dataset EGAD00001011282

• Single-cell RNA sequencing data of peripheral blood mononuclear cells obtained from 30 ATL patients, 11 HTLV-1-infected asymptomatic carriers, and 4 healthy donors.

  Single-cell RNA sequencing (scRNA-seq) data of peripheral blood mononuclear cells (PBMCs) obtained from 30 ATL patients (34 samples including 4 sequential ones), 11 HTLV-1-infected asymptomatic carriers, and 4 healthy donors.

  Dataset EGAD00001007015

• The natural history of clonal haematopoiesis: phase 6 targeted

  Deep targeted sequencing of 56 genes associated with clonal haematopoiesis and haematological malignancy in peripheral blood-derived DNA from 11 older adults, each previously sampled 2-5 times over the preceding ~13 years.

  Dataset EGAD00001007683

• Genome-wide data for 11 Roma individuals

  This dataset includes genome-wide autosomal array data for 11 Iberian Roma individuals used in the Merchero project.

  Dataset EGAD00001007773

• Target sequencing of 11 hereditary breast cancer genes in Japanese

  We performed a case control association study for variants in coding regions of 11 hereditary breast cancer genes in 7,051 female unselected breast cancer patients, 11,241 female controls, 53 male patients, and 12,490 male controls of Japanese ancestry. The 11 genes were ATM, BRCA1, BRCA2, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, and TP53.

  Study JGAS000140

• Human Single-Oocyte Transcriptome - Control and Cannabis Treated

  RNAseq data of human single oocytes exposed to THC and its metabolites, (mean concentration measured in the follicular fluid, THC1, n=95, 25 ng/mL Δ9-THC, 5 ng/mL 11-OH-THC, 50 ng/mL 11-COOH-THC) or a supraphysiologic, THC2, n=93, 100 ng/mL Δ9-THC, 50 ng/mL 11-OH-THC, 200 ng/mL 11-COOH-THC).

  Dataset EGAD50000001534

• Whole genome sequencing, DNA methylation, and gene expression data from gastrointestinal stromal tumor 30 patients

  We performed WGS along with genome-wide DNA methylation and gene expression analyses in 30 GIST cases to determine the genomic and epigenomic differences between KIT exon 11 557���558 deletions and other KIT exon 11 mutations.

  Study JGAS000604

• RNAseq of samples from CLL patients treated with ibrutinib in vivo

  The dataset contains RNA sequencing data from 22 paired samples of 11 patients before and during ibrutinib therapy (median time on therapy 2 weeks; range 1-12 weeks). The sequencing was performed in two batches.

  Dataset EGAD50000000879

• Pheochromocytoma paraganglioma single nuclei RNA-seq

  Single nuclei RNA sequencing (snRNA-seq) on tissue samples from 11 patients (SDHB and RET). Files are fastq files of 10x-5'scRNAseq libraries.

  Dataset EGAD00001008739

• Whole exome sequencing of advanced gastric cancer

  To define the cellular characteristics of malignant ascites of advanced gastric cancer patients and search for therapeutic strategies, we obtained 5 malignant ascites and 1 cerebrospinal fluid from five patients with gastric cancer. We analyzed single-cell RNA-seq data of 180 cells from 4 malignant ascites and 1 cerebrospinal fluid metastasis using Fluidigm® C1™ System. Whole exome sequencing data was also generated from blood or tumor tissue.

  Dataset EGAD00001005740

• Human Embryonic Multi-tissue ChIP-seq (Manchester)

  Histone ChIP-seq of 13 human embryonic tissues from weeks 6-8 of gestation. H3K4me3, H3K27me3 and H3K27ac. Biological replicates (n=2) for 11 tissues. Tissues (n): Brain (2); Retinal Pigmented Epithelium (eye)(2); Palate(2); Tongue (1); Left ventricle (heart)(2); Lung(2); Liver(2); Pancreas (2*); Stomach(1); Upper limb (2); Lower limb (2); Adrenal gland (2); Kidney (2)

  Dataset EGAD00001004335

• Whole genome sequencing of 76 tumor and normal samples from 11 SI-NET patients

  We have sampled 11 patients with multifocal SI-NETs. The complete genome sequences of 65 tumor and tissue samples including 42 intestinal lesions, 14 adjacent lymph node metastases, 5 distant metastases, as well as of 4 normal tissue and 11 normal blood samples were determined. This allowed elucidation of phylogenetic relationships between tumors within individual patients.

  Study EGAS00001005096

• UK10K_NEURO_FSZ REL-2012-11-27

  UK10K_NEURO_FSZ REL-2012-11-27

  Dataset EGAD00001000318

• Transcriptomics of PPD and Control LCLs Exposed to Steroid Hormones

  Lymphoblastoid cell lines (LCLs) were derived from women with (n=11) and without (n=9) past postpartum depression (PPD) and compared transcriptomically in two studies. Data provided represents: 1) normalized RNA-seq expression (CPM) or 2) Ampliseq-RNA Expression (CPM).The two studies are described below.1) The first examined estradiol (E2) and progesterone (P) hormone conditions mimicking pregnancy and parturition: supraphysiologic E2+P-addback; supraphysiologic E2+P-withdrawal; and no added E2+P (Baseline). RNA-sequencing identified unique differentially expressed genes (DEGs, p2) The second exposed control and PPD LCLs to ALLO or DMSO vehicle for 60 hours and used Ampliseq to detect differentially expressed genes (DEGs, pnominal

  Study phs003820

• MutaSeq data for A.10-12

  MutaSeq was applied to CD34+ cells from patient samples A.10, A.11 and A.12 of the study. The protocol followed is described in https://doi.org/10.1038/s41467-021-21650-1 and in the methods of the manuscript

  Dataset EGAD00001010189

• Codelink_HWG_CLD_B

  Codelink Human Whole Genome from Blood taken at 72 hours after birth (11 cases)

  Dataset EGAD00010001424

• Immune induction strategies to enhance the sensitivity to PD-1 blockade in metastatic triple negative breast cancer: the TONIC-trial

  The response rate in metastatic triple negative breast cancer (TNBC) to PD-1 blockade is low, highlighting an urgent clinical need for strategies that render the TNBC tumor microenvironment (TME) more sensitive to PD-1 blockade. Immunomodulatory mechanisms have been proposed for both chemotherapy and irradiation, but it has not been established whether these therapies may improve efficacy of PD-1 blockade by favorably changing the TME. In the first stage of this adaptive, non-comparative phase II trial (TONIC-trial; NCT02499367), 67 patients with metastatic TNBC were randomized to nivolumab without induction or to one of four induction treatments, consisting of irradiation of one metastatic lesion (3x8 Gy) or a two- week low-dose regimen of cyclophosphamide, cisplatin or doxorubicin, all followed by nivolumab. In the overall cohort of 66 evaluable patients, the objective response rate (ORR; iRECIST16) was 20% (95% CI: 11%-31%), with two complete responses and 11 partial responses. The majority of clinical responses were observed on nivolumab in the cisplatin (ORR 23%; 3/13) and doxorubicin (ORR 35%; 6/17) cohorts. After doxorubicin and cisplatin induction, we detected an upregulation of immune-related genes, involved in PD-1/PD-L1, and T-cell cytotoxicity pathways. This was further supported by enrichment among upregulated genes related to inflammation, JAK-STAT and TNFα-signaling after doxorubicin. In addition, we observed a trend towards increased T-cell infiltration, measured using T-cell receptor (TCR) sequencing, after doxorubicin. Together, the clinical and translational data of this study testing different immune induction strategies prior to nivolumab suggest that short-term doxorubicin and cisplatin may induce a more favorable TME and increase the likelihood of response to PD-1 blockade in TNBC. These data warrant further confirmation in TNBC and exploration of induction treatments prior to PD-1 blockade in other cancer types.

  Study EGAS00001003535

• Correlative Studies for Protocol #14-C-0059: T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Patients with GD2+ Solid Tumors, a Collaboration with CIMAC-CIDC

  This study is a retrospective correlative analysis of immune cell phenotypes in samples from a Phase I clinical trial (NCT02107963) of GD2 CAR-T cells (GD2-CAR.OX40.28.z.iC9) in children and young adults with osteosarcoma and neuroblastoma. The study was a 3+3 dose-escalation study with four dose levels (1 x 10(5) transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg). Apheresis and final manufactured GD2 CAR-T product samples were analyzed by bulk RNA sequencing and ATAC sequencing. The patients were stratified into good CAR-T expanders (peak CAR-T expansion >1000 GD2 CAR copies/100ng DNA) and poor CAR-T expansion (peak CAR-T expansion Increased naïve T cell subsets in baseline apheresis are associated with patients who experienced good CAR T cell expansion A T cell exhaustion signature was observed in the manufactured GD2 CAR-T product and may have contributed to lack of efficacy observed in this trial Increased myeloid-derived suppressor cell (MDSC) signatures were observed in patients with poor CAR-T expansion CAR-T product in good expanders displayed increased AP-1 factor transcription factor motifs, such as BATF, JUN, and FOS Data provided in dbGaP for this study include: Bulk RNA-Seq data for 11 pre-treatment peripheral blood and 11 GD2 CAR-T product from 14 patients. ATAC sequencing of 22 peripheral blood samples and 5 GD2 CAR-T products from 14 patients.

  Study phs003455

• BLUEPRINT release August 2016, Bisulfite-Seq for precursor lymphocyte of B lineage, on genome GRCh38

  Bisulfite-Seq data for 1 precursor lymphocyte of B lineage sample(s). 11 run(s), 2 experiment(s), 2 analysis(s) on human genome GRCh38. Part of BLUEPRINT release August 2016. Analysis documentation available at http://ftp.ebi.ac.uk/pub/databases/blueprint/releases/20160816/homo_sapiens/README_bisulphite_analysis_CNAG_20160816

  Dataset EGAD00001002291

• Identifying mutations in patient-derived melanoma DCC lines

  To identify mutations that cause resistance, we analyzed two patient-derived cell lines: Mel-DCC-11 (the parental line, sensitive to the BRAF inhibitor) and Mel-DCC-11-R (resistant to the BRAF inhibitor). We employed targeted-panel sequencing to examine the coding sequences of 410 cancer-associated target genes.

  Study EGAS50000001225

• UK10K_NEURO_ASD_TAMPERE REL-2012-11-27

  UK10K_NEURO_ASD_TAMPERE REL-2012-11-27

  Dataset EGAD00001000314

• UK10K_NEURO_FSZNK REL-2012-11-27

  UK10K_NEURO_FSZNK REL-2012-11-27

  Dataset EGAD00001000332

• UK10K_NEURO_ASD_MGAS REL-2012-11-27

  UK10K_NEURO_ASD_MGAS REL-2012-11-27

  Dataset EGAD00001000312

• UK10K_NEURO_ASD_SKUSE REL-2012-11-27

  UK10K_NEURO_ASD_SKUSE REL-2012-11-27

  Dataset EGAD00001000313

• UK10K_NEURO_ASD_BIONED REL-2012-11-27

  UK10K_NEURO_ASD_BIONED REL-2012-11-27

  Dataset EGAD00001000310

• UK10K_NEURO_ASD_FI REL-2012-11-27

  UK10K_NEURO_ASD_FI REL-2012-11-27

  Dataset EGAD00001000311

• UK10K_NEURO_ASD_GALLAGHER REL-2012-11-27

  UK10K_NEURO_ASD_GALLAGHER REL-2012-11-27

  Dataset EGAD00001000316

• UK10K_NEURO_IMGSAC REL-2012-11-27

  UK10K_NEURO_IMGSAC REL-2012-11-27

  Dataset EGAD00001000320

• UK10K_NEURO_IOP_COLLIER REL-2012-11-27

  UK10K_NEURO_IOP_COLLIER REL-2012-11-27

  Dataset EGAD00001000321

• UK10K_NEURO_UKSCZ REL-2012-11-27

  UK10K_NEURO_UKSCZ REL-2012-11-27

  Dataset EGAD00001000335

• 11 plasma cases and 4 urine cases (mouse)

  11 plasma cases and 4 urine cases (mouse)

  Dataset EGAD00001009829

• Multi-region sequencing of RCC with VTT and metastasis using WES and RNAseq

  This dataset contains multi-region sequencing of 16 RCC patients with venous tumor thrombus (VTT), 11 of which were either metastatic on diagnosis or recurred with metastasis. Whole exome sequencing is available for 94 samples across all 16 patients, including 1 matched normal sample per patient, 2-3 primary tumor samples per patient, 1-2 VTT samples per patient, and 0-3 metastasis samples per patient (metastatic lesions were only sampled for 8 of the 11 metastatic patients). RNAseq, generated by exome capture, is available for 67 samples across 12 patients, including 0-1 matched normal samples per patient, 3 primary tumor samples per patient, 0-1 VTT samples per patient, and 0-3 metastasis samples per patient (RNAseq was only available for 4 of the 8 patients from whom metastatic lesions were sampled).

  Dataset EGAD00001008441

• UK10K_RARE_NEUROMUSCULAR REL-2012-11-27

  UK10K_RARE_NEUROMUSCULAR REL-2012-11-27

  Dataset EGAD00001000298

• UK10K_NEURO_ABERDEEN REL-2012-11-27

  UK10K_NEURO_ABERDEEN REL-2012-11-27

  Dataset EGAD00001000315

• UK10K_NEURO_EDINBURGH REL-2012-11-27

  UK10K_NEURO_EDINBURGH REL-2012-11-27

  Dataset EGAD00001000317

• UK10K_NEURO_GURLING REL-2012-11-27

  UK10K_NEURO_GURLING REL-2012-11-27

  Dataset EGAD00001000319

• Paired-end snATAC-seq analysis of the 3D spatially mapped GBM samples.

  Dataset contains 11 paired-end snATAC-seq samples from 4 patients.

  Dataset EGAD00001010313

• UK10K_OBESITY_GS REL-2012-11-27

  UK10K_OBESITY_GS REL-2012-11-27

  Dataset EGAD00001000309

• UK10K_NEURO_MUIR REL-2012-11-27

  UK10K_NEURO_MUIR REL-2012-11-27

  Dataset EGAD00001000322

• UK10K_RARE_HYPERCHOL REL-2012-11-27

  UK10K_RARE_HYPERCHOL REL-2012-11-27

  Dataset EGAD00001000295

• UK10K_RARE_CILIOPATHIES REL-2012-11-27

  UK10K_RARE_CILIOPATHIES REL-2012-11-27

  Dataset EGAD00001000296

• UK10K_RARE_SIR REL-2012-11-27

  UK10K_RARE_SIR REL-2012-11-27

  Dataset EGAD00001000334

• UK10K_OBESITY_SCOOP REL-2012-11-27

  UK10K_OBESITY_SCOOP REL-2012-11-27

  Dataset EGAD00001000336

• Bulk ATAC data

  Bulk ATAC libraries were generated for patient samples A.1, A.3, A.5, A.6, A.7, A.11, A.12, A.13 and A.15. For each patient a library of CD3- cells (myeloid cells, considered tumor cells) and CD3+ cells (T cells, considered healthy) were generated.

  Dataset EGAD00001010188

• RRBS sequencing data of ovarian cancer, breast cancer, control tissues, and white blood cell DNA.

  The dataset comprises 8 breast cancer, 11 ovarian cancer, 1 benign tumour, 18 normal tissue, 2 endometrium, and 23 white blood cell samples. Genome wide methylation analysis was performed by Reduced Representation Bisulfite Sequencing (RRBS) on Illumina HiSeq 2500. Data is provided as FASTQ files

  Dataset EGAD00001003822

• WES of probands in KLB project

  These are the vcf files of exome sequencing of the two probands who were found to harbor mutations in KLB. Sample: EGAN00001564799 is the proband 1; Sample: EGAN00001564800 is the proband 11 in the KLB paper. Exome capture was performed using the SureSelect All Exon capture (Agilent Technologies, Santa Clara, CA USA) and sequenced on the HiSeq2500 (Illumina, San Diego CA USA).

  Dataset EGAD00001003463

• UK10K_RARE_CHD REL-2012-11-27

  UK10K_RARE_CHD REL-2012-11-27

  Dataset EGAD00001000294

• UK10K_RARE_THYROID REL-2012-11-27

  UK10K_RARE_THYROID REL-2012-11-27

  Dataset EGAD00001000329

• Single-cell RNA-seq of peripheral blood mononuclear cells in classic Hodgkin lymphoma

  Abstract: Classic Hodgkin lymphoma (cHL) is a largely MHC class I-negative tumor with recurrent 9p24.1/ PD-L1/ PD-L2 copy gains and the highest reported response rates to PD-1 blockade. We utilized scRNA sequencing to characterize the peripheral immune response to PD-1 blockade and more broadly define non-CD8+ dependent mechanisms of immune evasion in cHL. Peripheral blood mononuclear cells were obtained from 20 patients with relapsed/refractory (R/R) cHL treated with PD-1 blockade (nivolumab) on the CheckMate 205 clinical trial (paired samples from cycle 1 day 1 [C1D1] and cycle 4 day 1 [C4D1]), 11 patients with newly diagnosed, previously untreated cHL and 13 healthy donors.

  Dataset EGAD00001011360